METACRINE
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.
METACRINE
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.metacrine.com
Total Employee:
11+
Status:
Active
Contact:
(858) 369-7800
Email Addresses:
[email protected]
Total Funding:
173 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Adlai Nortye
Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immunovant
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
K2 HealthVentures
K2 HealthVentures investment in Debt Financing - Metacrine
Polaris Partners
Polaris Partners investment in Series C - Metacrine
ArrowMark Partners
ArrowMark Partners investment in Series C - Metacrine
Franklin Templeton Investments
Franklin Templeton Investments investment in Series C - Metacrine
LifeSci Venture Partners
LifeSci Venture Partners investment in Series C - Metacrine
Deerfield Capital Management
Deerfield Capital Management investment in Series C - Metacrine
ARCH Venture Partners
ARCH Venture Partners investment in Series C - Metacrine
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - Metacrine
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Metacrine
Invus
Invus investment in Series C - Metacrine
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-24 | Metacrine Announces Executive Leadership Changes |
Official Site Inspections
http://www.metacrine.com Semrush global rank: 9.41 M Semrush visits lastest month: 160
- Host name: 70.31.225.35.bc.googleusercontent.com
- IP address: 35.225.31.70
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Metacrine"
Metacrine - Crunchbase Company Profile & Funding
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most …See details»
Metacrine Inc (MTCR) Profile - The Globe and Mail
See the company profile for Metacrine Inc (MTCR) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Leadership & Board of Directors - Metacrine
© 2025 Metacrine | 231 Market Pl, Suite 373, San Ramon, CA 94583 Leadership & Board of Directors; Investors Financials & Filings; Sec Filings; Investor ResourcesSee details»
Metacrine, Inc. - LinkedIn
Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases.See details»
Metacrine Strengthens Leadership Team with Key Appointments
Sep 2, 2020 Metacrine Strengthens Leadership Team with Key Appointments . SAN DIEGO, September 2, 2020 — Metacrine, Inc., a clinical-stage biopharmaceutical company focused on …See details»
Metacrine - Contacts, Employees, Board Members, Advisors
Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs. ... Experience the new Crunchbase, powered by AI . …See details»
Metacrine, Inc. (MTCR) Company Profile & Facts - Yahoo Finance
See the company profile for Metacrine, Inc. (MTCR) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Metacrine Announces Appointment of Dr. Ken Song as President …
San Diego, CA – Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced …See details»
Metacrine Company Profile - Office Locations, Competitors ... - Craft
Metacrine is a biotech company developing innovative therapeutics for metabolic diseases. The company is led by an experienced management team and backed by leading institutional …See details»
Metacrine (USA) Funding: $173M - medicalstartups.org
Apr 2, 2025 Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. …See details»
Metacrine - LifeScienceHistory.com
Metacrine.com. 3985 Sorrento Valley Blvd., Suite C, San Diego, CA 92121. Company Info Phone (858) 281-4948 Year Established 2014 Ticker MTCR Exchange NASDAQ. Contacts Michael …See details»
Metacrine, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Metacrine, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 32 news, and 3 literature, Technology Platform:Chemical drugs, Small molecule drug, …See details»
Metacrine - Funding, Financials, Valuation & Investors - Crunchbase
Metacrine is registered under the ticker NASDAQ:MTCR . Their stock opened with $13.00 in its Sep 15, 2020 IPO. Metacrine is funded by 15 investors. K2 HealthVentures and Polaris …See details»
Metacrine Updates IBD Clinical Development Strategy and …
Feb 11, 2022 The restructuring includes a staff reduction of approximately 50% primarily consisting of the Company’s research organization. As a result, Metacrine has also …See details»
Metacrine - VentureRadar
Metacrine's lead program for non-alcoholic steatohepatitis (NASH), MET409, focuses on the farnesoid X receptor (FXR) and is based on a novel non-bile acid chemical scaffold. Additional programs are underway in irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD) and the company has a research collaboration with Novo Nordisk in type 2 …See details»
Metacrine Broadens Management Team with Two Key Hires
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced two new …See details»
Metacrine Announces Executive Leadership Changes
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated... Metacrine Announces Executive …See details»
mtcr-ex991_6.htm - SEC.gov
Exhibit 99.1 . METACRINE Announces executive leadership changes. SAN DIEGO – February 24, 2022 – Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer.Ms. Millican will …See details»
Metacrine, Inc. (MTCR)
Find the latest Metacrine, Inc. (MTCR) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Metacrine Updates IBD Clinical Development Strategy and
Feb 11, 2022 The restructuring includes a staff reduction of approximately 50% primarily consisting of the Company’s research organization. As a result, Metacrine has also discontinued preclinical ...See details»